anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants will be informed of the intent of the study in the initial e-mail introduction and invitation of participation. Participants will be given the opportunity to ask questions about the study by asking the research assistants, whose names and email addresses will be given. Within the initial email introduction/invitation of participation, participants will be given the name and contact information of the research assistants and will be instructed to direct all questions regarding the survey to them. All data received from the survey participants will be returned de-identified. None of the data collected will be traceable to the survey participants. Participants will be provided the research assistants' email addresses and can contact them should they be interested in receiving any results from the study. The benefits of the study are to advance the overall role of Occupational Therapy services within head start facilities. This study could further understandings of how and / or why certain concepts should / shouldn't be used, could assist administrators in developing quality programming, and contribute to the body of knowledge in Occupational Therapy in Head Start programs. The research assistants' e-mail addresses will be provided in the consent forms with a statement saying that they will be able to contact her via e-mail should they be interested in receiving any results from the study.Informed consent will be obtained through the initial email introduction and formal request for participation. Participants will be provided study information on the first page of the survey and will indicate their consent by clicking "yes" or "no" before beginning the survey.
This study is a prospective, randomized (1:1), controlled multisite study of MBSR in 180 veterans with PTSD. The investigators will compare the clinical outcomes of MBSR to a credible group therapy control condition called Present Centered Group Therapy (PCGT). The investigators will to evaluate the efficacy of MBSR in the treatment of PTSD, as defined by the Clinician Administered PTSD Scale (CAPS), a gold standard measure that is clinically relevant to PTSD. The CAPS will be rated by a trained assessor who is blind to the whether or not the participant receives the MBSR or PCGT intervention. Secondarily, the investigators will evaluate the effects of MBSR on mindfulness, depression, PTSD symptom clusters, rates of response and evaluate the safety and tolerability of MBRS. The investigators will also explore the subjects' acceptance of and satisfaction with MBSR, whether or not the subjects' treatment preference influences outcome; the stress-immunological-biomarkers as they relate to treatment outcome; and the durability of therapeutic effects of MBSR in the treatment of PTSD.

Study Design Overview: Male and female subjects from Active Duty, Reserves, National Guard and/or Veterans with a diagnosis of PTSD will be prospectively randomized 1:1 to receive either MBSR Group therapy or Present Centered Therapy (PCGT) Group (control) for 8 weeks. A cluster of at least 12 participants will be randomized individually to either MBRS or PCGT group therapies, which results in at least 6 participants in each intervention group. A total of 30 groups (15 MBSR Groups and 15 PCGT Groups) are anticipated across three clinical research sites involving at least three different MBSR and three different PCGT instructors/therapists. Outcome assessments (single-blind CAPS and self-report measures) will be obtained at baseline, week 3, week 6, and week 9 (primary endpoint). These assessments will be repeated post-acute treatment at week 16 as an exploratory measure of short-term durability effects.
The present invention relates to levocarrimycin, its pharmaceutical compositions, preparation methods and pplication. Levocarrimycin is a mixture of isovalerylspiramycin III, II and I as main components and contains some isobutyrylspiramycin III and II, butyrylspiramycin III and II, propionylspiramycin III and II, as well as acetylspiramycin III and II, among which, the content of isovalerylspiramycin III is no less than 30 wt%, the total content of isovalerylspiramycin III, II and I is no less than 60 wt%, and the content of acylspiramycin is 80-98 wt%. Specific optical rotation of said levocarrimycin is [.alpha.]D = -52° - -57° in the solution of 0.02g/ml chloroform at temperature of 25°C. The present invention also relates to the crystalline compound of isovalerylspiramycin III, II or I in levocarrimycin, and pharmaceutical compositions containing the said levocarrimycin. In present invention, the active components in levocarrimycin or its pharmaceutical compositions have optical activity and excellent anti-infective effect.
The invention discloses a Chinese herbal compound extract with an effect of resisting proliferation of mammary gland, and a preparation method thereof. The Chinese herbal compound extract is prepared by the following raw materials by weight: 10-20 parts of radix bupleuri, 10-20 parts of rhizoma cyperi, 5-15 parts of rheum officinale, 5-15 parts of pericarpium citri reticulatae viride, 5-15 parts of rhizoma chuanxiong, 5-15 parts of rhizoma curcumae, 5-15 parts of fritillary bulb, 10-20 parts of angelica sinensis, 10-20 parts of white peony root, 5-15 parts of ground beetle and 5-15 parts of cowherb seed. The Chinese herbal compound extract is prepared by a scientific formula, treats based on syndrome differentiation according to the theory of traditional Chinese medicine. Active components and an optimum preparation process are screened out by adopting a modern chemical component extraction separation and a pharmacological experiment tracking method. Pharmacological experiments show that the Chinese herbal compound extract provided by the invention has very good effect for treating the proliferation of the mammary gland, and has no toxic and side effect. The preparation method provided by the invention is stable in process and good in repeatability. The prepared extract is stable in quality. A plurality of oral drug preparations can be prepared and the oral drug preparations are convenient for clinic use.
Chemotherapy 1: This group will receive Adriamycin (60mg/m2) and Cytoxan (600mg/m2) concurrently on day 1 every 2 weeks for 4 cycles followed by Taxol (175mg/m2) on day 1 every 2 weeks for 4 cycles. Patients on this regimen who randomize to the experimental ("acupuncture") group will undergo acupuncture on the morning of every treatment for a total of 8 acupuncture sessions. Both groups will complete a MDASI on day 3 (+/- 1 days) of each cycle of chemotherapy for a total of 8 MDASI forms.
The invention relates to method and system for creating a data model. The method includes receiving input to create process entity via first User Interface (UI). The process entity is configured to act as first-class citizen. The method further includes creating node corresponding to process entity to generate nodal network via second UI; dynamically receiving attributes associated with selected entity via the first UI; annotating node corresponding to the selected entity based on the attributes received via the second UI; and dynamically creating link between first and second nodes in the nodal network via the second UI. The second UI includes nodes. The link creation includes receiving selection of the first node; receiving selection of the second node; generating the link between the first node and the second node; and receiving direction input associated with the link; and defining direction of the link between the first and second nodes.
Participants will be exposed to electronic hookah aerosol. To mitigate the impact of carryover effects, the exposure sessions will be separated by a minimum of 7-days.
Heart failure is a complex clinical syndrome characterized by a high prevalence and incidence in populations at greatest risk and, therefore, with a significant social and economic impact. Randomized clinical trials, meta-analyzes, observational studies and controlled trials clearly demonstrated that the neuro-hormonal therapy is highly effective in reducing mortality, hospitalization and improving quality of life. In recent years the electrical therapy is playing an increasingly important role in the treatment of patients with chronic heart failure. Such importance is mainly due to the possibility of preventing sudden cardiac death by implanting an ICD and to correct the deleterious effects of electrical dyssynchrony and / or left ventricular mechanics by CRT. The CRT has proven an effective tool in reducing mortality, reducing symptoms and improving quality of life in patients already receiving optimal medical therapy. Despite the undoubted benefits that the electrical treatment has added to conventional medical therapy, a high percentage of patients does not benefit in terms of clinical and echocardiographic. The identification of non-responders to CRT is crucial in order not to submit the patients to an unnecessary and costly device whose electrical therapy proves to be ineffective. The reason for lack of response is still unclear but factors such as lead placement, device-settings and the degree of dyssynchrony before implant seems to be important. The purpose of the study is to collect some parameters (clinical, electrical, radiographic, echocardiographic and ECG) able to predict response to cardiac resynchronization therapy.
<P>PROBLEM TO BE SOLVED: To provide a dental model fabrication method which can shorten the time of curing an impression material, a disinfection/sterilization step, and a long gypsum curing time for abridging working steps of fabricating a dental model and is simple and low-cost.  <P>SOLUTION: For the purpose of achieving a low-cost dental model fabrication method, the method is characterized in that a material used in the dental model fabrication is mixed with alum water. Alum water cannot only accelerate the time of curing an impression material or gypsum but also can markedly abridge working steps in virtue of its sterilization action and astringent action. The subject of an impression material mixed with the alum water is an impression material composition based on mainly a soluble alginate and is generally effective dental gypsum. The alum water is a desirably an aqueous solution of 0.01-5 wt.% alum concentration. The concentration of the alum water is adjusted according to the type, i.e., characteristics, of an impression material or gypsum.  <P>COPYRIGHT: (C)2011,JPO&INPIT
The invention belongs to the field of medical biology engineering, and particularly relates to a method for effectively multiplying gamma delta T cells by stimulating peripheral blood in vitro and application of the method. The method comprises the step of using feeder cells, an OKT3 (ornithine ketoacid transaminase) antibody, interleukin-2 and zoledronic acid. The feeder cells are formed by specifically inserting CD64, CD86 and CD137L genes in a target site of a genome of the feeder cells. After the zoledronic acid and the nterleukin-2 are used for increasing the proportion of the gamma delta T cells of the peripheral blood, protein products of genes, the OKT3 antibody and the interleukin-2 act in a combined manner, and the gamma delta T cells can be stimulated so that a large amount of gamma delta T cells can be multiplied. The multiplied gamma delta T cells can be used for killing tumor cells which are pretreated by the zoledronic acid, or the tumor cells can be directly killed by modifying and expressing chimeric antigen receptors (CAR) via a genetic engineering means. The gamma delta T cells which are obtained by the method have complete anti-tumor cytotoxicity, and can kill solid tumor cells and non-solid tumor cells.
The present invention relates to a titration package for providing at least one pharmaceutical composition in at least two different dosages. The titration package comprises at least two sets. Each set comprises at least three individually addressable regions. Each addressable region preferably comprises or is represented by a pharmaceutical composition, preferably a tablet. The dosage of the pharmaceutical composition is the same within each of the at least two sets (“common dosage”), while the dosages of the pharmaceutical compositions are different for one of the at least two sets compared to at least one other of the at least two sets. The arrangement of the at least two sets is not a matrix-like arrangement.
In 2008, medical cost of osteoporosis and osteoporosis-related fractures was estimated to be $22 billion. This is further expected to rise because of an increase of 20% in population with osteoporosis, amounting to 12 million adults over the age of 50 years, by 2020, out of which 80% will be postmenopausal women. Unfortunately, benefits due to pharmacological interventions have plateaued. Consequently, there is a critical need to identify complementary therapies to enhance the treatment of low bone mass in older adults. The aim of this study is to examine the feasibility of novel progressive muscle resistance exercise in postmenopausal women with low bone mass. Muscle will be assessed via imaging techniques and isokinetic dynamometer. Physical activity will be assessed via activity monitors. Blood will be collected to assess bone and muscle biomarkers. Balance will be assessed via clinical and biomechanical tests. Testing will be performed at 4 time points: baseline, 1 month, 3 month, and 6 months except imaging which will be done at the baseline and 6 months. The findings from this study will help us to understand the feasibility of resistive muscle exercise program in postmenopausal women with low bone mass.
The embodiments provide a process for preparing a product range containing at least a first and second inhalable dry powder medicament. The first and second inhalable medicament contain the same active ingredient at different doses, although the active ingredient is always within the range of 0.1-5.5% w/w, based on the total weight of the medicament. The amounts of the active ingredient in the first and second medicament define a dose ratio, and the delivered doses of the active ingredient in the first and second medicament define a delivered dose ratio. The medicament also contains a coarse carrier and a fine excipient. The dose ratio is substantially the same as the delivered dose ratio, and this is achieved by adjusting the amount of the fine excipient in the first and second medicament. The amount of the active ingredient and the fine excipient in total does not exceed 15% w/w, based on the total weight of the medicament.
Information for Patients:   
The patient (or parent/care giver) should be instructed to seek medical advice whenever nausea, vomiting, persistent headache, insomnia or rapid heart beat occurs during treatment with theophylline, even if another cause is suspected. The patient should be instructed to contact their healthcare professional if they develop a new illness, especially if accompanied by a persistent fever, if they experience worsening of a chronic illness, if they start or stop smoking cigarettes or marijuana, or if another healthcare professional adds a new medication or discontinues a previously prescribed medication. Patients should be informed that theophylline interacts with a wide variety of drugs (see Table II). The dietary supplement St. John's Wort (Hypericum perforatum) should not be taken at the same time as theophylline, since it may result in decreased theophylline levels. If patients are already taking St. John's Wort and theophylline together, they should consult their healthcare professional before stopping the St. John's Wort, since their theophylline concentrations may rise when this is done, resulting in toxicity. Patients should be instructed to inform all healthcare professionals involved in their care that they are taking theophylline, especially when a medication is being added or deleted from their treatment. Patients should be instructed to not alter the dose, timing of the dose, or frequency of administration without first consulting their healthcare professional. If a dose is missed, the patient should be instructed to take the next dose at the usually scheduled time and to not attempt to make up for the missed dose.

Patients should be instructed to take this medication each morning at approximately the same time and not to exceed the prescribed dose.

Patients who require a relatively high dose of theophylline should be informed of important considerations relating to time of drug administration and meal content (see PRECAUTIONS, Drug/Food Interactions; and DOSAGE AND ADMINISTRATION).
The exercise intervention group perform three sessions of HIIT per week for 12 weeks. HIIT involves 4 times 4-minutes intervals at 85-95% of maximal heart rate (HRmax) with 3-minutes active breaks (\~60% HRmax) between the intervals. Two HIIT sessions are supervised at the NextMove core facility, and performed on treadmills or spinning bikes, while the last session of HIIT is unsupervised. In this unsupervised session, HIIT in a pool will be recommended based on the potential benefits gained from compression. The criteria for adequate compliance to the exercise intervention program will be set to ≥80%.
Phomopsis stem canker of cultivated sunflower (Helianthus annuus L.) can be caused by multiple necrotrophic fungi in the genus Diaporthe, with Diaporthe helianthi and D. gulyae being the most common causal agents in the United States. Infection begins at the leaf margins and proceeds primarily through the vasculature, progressing from the leaf through the petiole to the stem, resulting in formation of brown stem lesions centered around the petiole. Sunflower resistance to Phomopsis stem canker is quantitative and genetically complex. Due to the intricate disease process, resistance is possible at different stages of infection, and multiple forms of defense may contribute to the overall level of quantitative resistance. In this study, sunflower lines exhibiting field resistance to Phomopsis stem canker were evaluated for stem and leaf resistance to multiple isolates of D. helianthi and D. gulyae in greenhouse experiments, and responses to the two species were compared. Additionally, selected resistant and susceptible lines were evaluated for petiole transmission resistance to D. helianthi. Lines with distinct forms of resistance were identified, and results indicated that responses to stem inoculation were strongly correlated (Spearman's coefficient 0.598, P < 0.001) for the two fungal species, while leaf responses were not (Spearman's coefficient 0.396, P = 0.076). These results provide a basis for genetic dissection of distinct forms of sunflower resistance to Phomopsis stem canker and will facilitate combining different forms of resistance to potentially achieve durable control of this disease in sunflower hybrids.
A computerized system that will allow healthcare providers to access the commercial paper market by "selling" their patient claims to asset backed commercial paper conduits. The system generates the statistical information on the historic collection experience of the provider's claims required by both the rating agencies and the sponsors of the conduits. This statistical information has two pieces: the net collectible value matrix showing the percentage of the claim actually paid by individual payers; and a collection histogram showing the timing of the payers payments from the date of initial billing. The system also generates the accounting detail necessary for controlling and auditing the provider's participation in the commercial paper conduit program. The system tracks "periodic pools" of claims so as to be able to reconcile advances, collections, interest expense, third party fees and cash settlements between conduits and providers. This statistical information has two pieces: the net collectible value matrix showing both the percentage of the claim actually paid by individual payors and the standard deviation of this percentage; and a collection histogram showing the timing of the payors' payments from the date of initial billing.
Subjects aged 3-5 years received 2 doses of GSK1562902A vaccine, lot 1. These subjects were enrolled in the Phase A of this NCT00502593 study (or study 107066). The GSK1562902A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
Participants will receive 15 mg pioglitazone on Day 1 (Period 1). On Day 8 (Period 2), participants will receive 1000 mg abiraterone acetate followed by 15 mg of pioglitazone one hour later.
Patients will be randomly assigned by central randomization in a 1:1 ratio to receive folinic acid (FA) or placebo starting 24h after each MTX dose for 24h. Oral FA 15 mg/dose or placebo will be given every 8h after MTX administration on day 1 (3 doses), and every 6h (4 doses) on days 3 and 6.
PURPOSE:To prepare the titled Panax ginseng takable as it is and having excellent preservability, by using Panax ginseng as a raw material, and drying the Panax ginseng to the state having crisp and not too hard palatability while keeping the original color, flavor, taste and active component of the Panax ginseng. CONSTITUTION:Raw Panax ginseng is dried at 40-80 deg.C under air flow to effect the partial dehydration and contraction of the skin part to a water-content of <=50wt%, and then, the water-content in the whole Panax ginseng is uniformized to 65-75wt%. In the case of using a dried Panax ginseng as the raw material, water is absorbed to the dried tissue so as to attain a water-content of 65- 75wt% to effect the swelling of the dried Panax ginseng. The conditioned Panax ginseng is fried in an oil at 70-120 deg.C under reduced pressure, i.e. a vacuum of <=30mm.Hg to a water-content of <=5wt%, and then the content of oil and fat is adjusted to 5-25wt% under reduced pressure. A medical Panax ginseng product having excellent taste and convenient to take can be prepared by this process. It is necessary that the tissue structure of the Panax ginseng before the oil-frying under reduced pressure is composed of a relatively dense skin tissue and a xylem having not too hard and moderately coarse tissue.
Patients with ACLF grade 1 and ACLF grade 2 on the background of alcoholic cirrhosis randomized to the DIALIVE arm will receive treatment in an intensive care (ICU) or renal dialysis unit setting. They will receive DIALIVE treatment according to a fixed treatment schedule over a period of 10 days post-randomization.
The static stretching protocol comprised eight exercises, performed for 30 seconds per bilateral muscle group (with the exception of the sitting toe touch and butterfly stretch), and included the hip, knee, and ankle. Each subject completed each stretch before progressing to the subsequent one. The stretches were maintained until the subject experienced mild discomfort, but not pain.